A correlation of thrombin generation assay and clot waveform analysis in patients on warfarin
Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters....
Saved in:
Published in | Hematology (Luxembourg) Vol. 27; no. 1; pp. 337 - 342 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Taylor & Francis
31.12.2022
Taylor & Francis Group |
Subjects | |
Online Access | Get full text |
ISSN | 1607-8454 1607-8454 |
DOI | 10.1080/16078454.2022.2043573 |
Cover
Loading…
Abstract | Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients.
A prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects.
54 samples were included covering an INR range from 1.33-6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, P<0.001; min2: r = 0.485, P<0.001; max2: r = 0.578, P<0.001; adjusted min1: r = 0.734, P<0.001, adjusted min2: r = 0.693, P<0.001; adjusted max2: r = 0.751, P<0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, P = 0.087; min2: r = 0.326, P = 0.016; max2: r = 0.437, P<0.001; adjusted min1: r = 0.610, P<0.001, adjusted min2: r = 0.563, P<0.001; adjusted max2: r = 0.642, P<0.001).
We demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it's role in the evaluation of global haemostatic function. |
---|---|
AbstractList | Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients.
A prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects.
54 samples were included covering an INR range from 1.33-6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, P<0.001; min2: r = 0.485, P<0.001; max2: r = 0.578, P<0.001; adjusted min1: r = 0.734, P<0.001, adjusted min2: r = 0.693, P<0.001; adjusted max2: r = 0.751, P<0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, P = 0.087; min2: r = 0.326, P = 0.016; max2: r = 0.437, P<0.001; adjusted min1: r = 0.610, P<0.001, adjusted min2: r = 0.563, P<0.001; adjusted max2: r = 0.642, P<0.001).
We demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it's role in the evaluation of global haemostatic function. Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients. A prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects. 54 samples were included covering an INR range from 1.33-6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, <0.001; min2: r = 0.485, <0.001; max2: r = 0.578, <0.001; adjusted min1: r = 0.734, <0.001, adjusted min2: r = 0.693, <0.001; adjusted max2: r = 0.751, <0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, = 0.087; min2: r = 0.326, = 0.016; max2: r = 0.437, <0.001; adjusted min1: r = 0.610, <0.001, adjusted min2: r = 0.563, <0.001; adjusted max2: r = 0.642, <0.001). We demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it's role in the evaluation of global haemostatic function. Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients.OBJECTIVESThrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients.A prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects.PATIENTS/METHODSA prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects.54 samples were included covering an INR range from 1.33-6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, P<0.001; min2: r = 0.485, P<0.001; max2: r = 0.578, P<0.001; adjusted min1: r = 0.734, P<0.001, adjusted min2: r = 0.693, P<0.001; adjusted max2: r = 0.751, P<0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, P = 0.087; min2: r = 0.326, P = 0.016; max2: r = 0.437, P<0.001; adjusted min1: r = 0.610, P<0.001, adjusted min2: r = 0.563, P<0.001; adjusted max2: r = 0.642, P<0.001).RESULTS54 samples were included covering an INR range from 1.33-6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, P<0.001; min2: r = 0.485, P<0.001; max2: r = 0.578, P<0.001; adjusted min1: r = 0.734, P<0.001, adjusted min2: r = 0.693, P<0.001; adjusted max2: r = 0.751, P<0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, P = 0.087; min2: r = 0.326, P = 0.016; max2: r = 0.437, P<0.001; adjusted min1: r = 0.610, P<0.001, adjusted min2: r = 0.563, P<0.001; adjusted max2: r = 0.642, P<0.001).We demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it's role in the evaluation of global haemostatic function.CONCLUSIONWe demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it's role in the evaluation of global haemostatic function. Objectives Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients.Patients/Methods A prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects.Results 54 samples were included covering an INR range from 1.33–6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, P<0.001; min2: r = 0.485, P<0.001; max2: r = 0.578, P<0.001; adjusted min1: r = 0.734, P<0.001, adjusted min2: r = 0.693, P<0.001; adjusted max2: r = 0.751, P<0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, P = 0.087; min2: r = 0.326, P = 0.016; max2: r = 0.437, P<0.001; adjusted min1: r = 0.610, P<0.001, adjusted min2: r = 0.563, P<0.001; adjusted max2: r = 0.642, P<0.001).Conclusion We demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it’s role in the evaluation of global haemostatic function. |
Author | Cheong, May Anne Wong, Wan Hui Shim, Yuan Tying Tan, Chuen Wen Ng, Heng Joo See, Edmund Yeang, Shu Hui Lee, Lai Heng Kong, Ming Chai Koh, Sei Keng |
Author_xml | – sequence: 1 givenname: May Anne orcidid: 0000-0002-1333-6596 surname: Cheong fullname: Cheong, May Anne email: cheong.may.anne@singhealth.com.sg organization: Singapore General Hospital – sequence: 2 givenname: Chuen Wen surname: Tan fullname: Tan, Chuen Wen organization: Singapore General Hospital – sequence: 3 givenname: Wan Hui surname: Wong fullname: Wong, Wan Hui organization: Singapore General Hospital – sequence: 4 givenname: Ming Chai surname: Kong fullname: Kong, Ming Chai organization: Singapore General Hospital – sequence: 5 givenname: Edmund surname: See fullname: See, Edmund organization: Singapore General Hospital – sequence: 6 givenname: Shu Hui surname: Yeang fullname: Yeang, Shu Hui organization: Singapore General Hospital – sequence: 7 givenname: Sei Keng surname: Koh fullname: Koh, Sei Keng organization: Singapore General Hospital – sequence: 8 givenname: Yuan Tying surname: Shim fullname: Shim, Yuan Tying organization: Singapore General Hospital – sequence: 9 givenname: Lai Heng surname: Lee fullname: Lee, Lai Heng organization: Singapore General Hospital – sequence: 10 givenname: Heng Joo surname: Ng fullname: Ng, Heng Joo organization: Singapore General Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35255239$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkUtvFDEQhEcoiDzgJ4DmyGWDn_MQF6IIkkiRuMARWW1POzjy2ovtZbX_Hk9mFyEOcLGt8lfVUtd5cxJiwKZ5TcklJQN5RzvSD0KKS0YYq4fgsufPmrNZX80fJ3-8T5vznB9JJUlPXjSnXDIpGR_Pmm9XrYkpoYfiYmijbcv3FNfahfYBA6ZFhpxh30KYWuNjaXfwE21M66qA32eX24pvKoqh5LbyO0gWkgsvm-cWfMZXh_ui-frp45fr29X955u766v7lZFCltUw2A6lpYgj74UlugM7MjRAB9aBHiiBjlEcjNGyswQGMU6aGkmgF0Rzxi-auyV3ivCoNsmtIe1VBKeehJgeFKTijEfF9GiBU6CoqegNG1FrrNMHLXoqkNast0vWJsUfW8xFrV026D0EjNusWMd7XvctSEXfHNCtXuP0e_BxvRV4vwAmxZwTWmVceVppSeC8okTNZapjmWouUx3KrG75l_s44H--D4vPhbkl2MXkJ1Vg72OyCYJxWfF_R_wCNHu1zQ |
CitedBy_id | crossref_primary_10_33160_yam_2022_08_013 crossref_primary_10_1016_j_thromres_2025_109268 crossref_primary_10_33160_yam_2022_08_008 crossref_primary_10_1038_s41598_024_60098_3 crossref_primary_10_33086_ijmlst_v5i1_3064 |
Cites_doi | 10.1016/j.thromres.2019.03.022 10.1111/j.1538-7836.2006.01730.x 10.1186/1477-9560-1-7 10.1111/jth.14022 10.1186/1477-9560-13-1 10.1160/TH09-03-0180 10.1111/j.1538-7836.2005.01513.x 10.1002/rth2.12048 10.1111/j.1365-2141.2008.07279.x 10.1159/000073575 10.5482/HAMO-14-02-0016 10.1046/j.1365-2257.2002.00457.x 10.1055/s-0038-1657690 10.1111/j.1538-7836.2006.01848.x 10.1111/jth.12287 |
ContentType | Journal Article |
Copyright | 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2022 |
Copyright_xml | – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2022 |
DBID | 0YH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
DOI | 10.1080/16078454.2022.2043573 |
DatabaseName | Taylor & Francis Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1607-8454 |
EndPage | 342 |
ExternalDocumentID | oai_doaj_org_article_2b9fa31a1eb147c29ebbe6e58b4714e1 35255239 10_1080_16078454_2022_2043573 2043573 |
Genre | Research Article Journal Article |
GroupedDBID | --- 002 0YH 1~B 29I 36B 4.4 53G AALUX ABDBF ACGEJ ACUHS ADCVX ADXPE AENEX AIJEM AJWEG ALMA_UNASSIGNED_HOLDINGS ARJSQ BLEHA BOHLJ CCCUG CS3 DU5 E01 EAP EBC EBD EBS EMB EMK EMOBN EPL ESX F5P GROUPED_DOAJ H13 HCLVR HZ~ KTTOD M4Z MV1 OK1 P76 P7A P7B QZIEQ SV3 TDBHL TFL TFW TUS ~XQ AAFWJ AAYXX AFPKN CITATION 5VS ABUPF AGYJP AWYRJ CAG CGR COF CUY CVF CZDIS DRXRE ECM EIF EJD M46 NPM 7X8 |
ID | FETCH-LOGICAL-c545t-88f6e5f1ee9374f0b6af92eca1826ab810a621e8ccb56f0a849db1c50a740b323 |
IEDL.DBID | 0YH |
ISSN | 1607-8454 |
IngestDate | Wed Aug 27 01:32:23 EDT 2025 Fri Jul 11 01:22:05 EDT 2025 Wed Feb 19 02:26:13 EST 2025 Thu Apr 24 22:59:22 EDT 2025 Tue Jul 01 02:28:02 EDT 2025 Wed Dec 25 09:05:03 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Anticoagulants partial thromboplastin time thrombin blood coagulation tests warfarin |
Language | English |
License | open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c545t-88f6e5f1ee9374f0b6af92eca1826ab810a621e8ccb56f0a849db1c50a740b323 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-1333-6596 |
OpenAccessLink | https://www.tandfonline.com/doi/abs/10.1080/16078454.2022.2043573 |
PMID | 35255239 |
PQID | 2637320440 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_2b9fa31a1eb147c29ebbe6e58b4714e1 crossref_citationtrail_10_1080_16078454_2022_2043573 informaworld_taylorfrancis_310_1080_16078454_2022_2043573 pubmed_primary_35255239 proquest_miscellaneous_2637320440 crossref_primary_10_1080_16078454_2022_2043573 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-12-31 |
PublicationDateYYYYMMDD | 2022-12-31 |
PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-31 day: 31 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Hematology (Luxembourg) |
PublicationTitleAlternate | Hematology |
PublicationYear | 2022 |
Publisher | Taylor & Francis Taylor & Francis Group |
Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
References | CIT0010 CIT0001 CIT0012 CIT0011 CIT0003 CIT0014 CIT0002 CIT0013 CIT0005 CIT0004 CIT0015 CIT0007 CIT0006 CIT0009 CIT0008 |
References_xml | – ident: CIT0006 doi: 10.1016/j.thromres.2019.03.022 – ident: CIT0010 doi: 10.1111/j.1538-7836.2006.01730.x – ident: CIT0015 doi: 10.1186/1477-9560-1-7 – ident: CIT0008 doi: 10.1111/jth.14022 – ident: CIT0001 doi: 10.1186/1477-9560-13-1 – ident: CIT0014 doi: 10.1160/TH09-03-0180 – ident: CIT0005 doi: 10.1111/j.1538-7836.2005.01513.x – ident: CIT0012 doi: 10.1002/rth2.12048 – ident: CIT0009 doi: 10.1111/j.1365-2141.2008.07279.x – ident: CIT0007 doi: 10.1159/000073575 – ident: CIT0003 doi: 10.5482/HAMO-14-02-0016 – ident: CIT0004 doi: 10.1046/j.1365-2257.2002.00457.x – ident: CIT0013 doi: 10.1055/s-0038-1657690 – ident: CIT0011 doi: 10.1111/j.1538-7836.2006.01848.x – ident: CIT0002 doi: 10.1111/jth.12287 |
SSID | ssj0022070 |
Score | 2.3182316 |
Snippet | Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays.... Objectives Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global... |
SourceID | doaj proquest pubmed crossref informaworld |
SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 337 |
SubjectTerms | Anticoagulants Blood Coagulation - drug effects blood coagulation tests Blood Coagulation Tests - methods Humans Middle Aged partial thromboplastin time Prospective Studies thrombin Thrombin - drug effects warfarin Warfarin - pharmacology Warfarin - therapeutic use |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PSx0xEA7Fg_RStK36qi0Rel3dJLPZ7FFFkYKeKngpIckmXnSf-Fal_72TH_vQgrxLb0tIYJjMZr4vP74h5CdGUd-DElVTC15Bi1-2aSNLwWwifGtZ2tO9uJTnV_Drurl-Veor3gnL8sDZcYfcdsEIZhguKtA63nlrvfSNsrisgk_EB3PeRKYK1eJow_ReR9WHUUVNQdpD4fH1FWKEVrzJREmw_x-50vdBZ0o-ZxvkU0GN9Chbu0k--OEzWb8o5-JfyJ8j6mKZjXyxjc4DjeUP7pD10pukK52aESebv9QMPXW385E-mycfzcCWLExCsXvRWV1Q7P9sHgJS6eEruTo7_X1yXpXCCZVDQDRWSgX0UGDeI_iAUFtpQse9M5FMGKtYbSRnXjlnGxlqo6DrLXNNbVqoreBii6wN88HvENqCM46DYR0AeLAGEaMUIFXnueytnRGYnKhdURWPxS1uNSvio5PvdfS9Lr6fkYPlsPssq7FqwHGcoWXnqIqdGjBWdIkVvSpWZqR7Pb96TJsiIVcw0WKFAftTMGj8A-Oxihn8_HGhuRSt4LF094xs5yhZmhnFZpHqd9_-h_m75GO0KMtM7pG18eHRf0dINNofKfpfAJvbAr8 priority: 102 providerName: Directory of Open Access Journals |
Title | A correlation of thrombin generation assay and clot waveform analysis in patients on warfarin |
URI | https://www.tandfonline.com/doi/abs/10.1080/16078454.2022.2043573 https://www.ncbi.nlm.nih.gov/pubmed/35255239 https://www.proquest.com/docview/2637320440 https://doaj.org/article/2b9fa31a1eb147c29ebbe6e58b4714e1 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSIgLAspjeVRG6jUQ2xPHORbUalWpPVGJHirL9tq9lATtplT8e2YcZwVIVQ-9JZatjMfjzMPjbxjbRylarcCoqqmVrKDFJ9-05KWgNlGx9SLHdE9O9fIMjr83czbhpqRVkg-dJqCI_K-mze38Zs6I-0yYaAZyRETSXSrU-K16yB5Jwl5Hka7Pl1ufSyIx88Wd24b-o5Iycv9_uKW3W59ZCx09Y0-L-cgPpvV-zh7E_gV7fFIOyHfZxQEPVG9jynDjQ-JUB-EHur_8MgNM52Y0mN1vjvPn4WoY-Y37FYkMbJkQSjh2L4CrG479b9w6oU_dv2RnR4ffvi6rUkGhCmgZjZUxSccmiRjRCoFUe-1SJ2Nw5FU4b0TttBTRhOAbnWpnoFt5EZratVB7JdUrttMPfXzDeAvBBQlOdAAQwTs0HbUCbboo9cr7BYOZiTYUeHGqcnFlRUEhnXlvife28H7BPm2H_ZzwNe4a8IVWaNuZ4LFzw7C-tGW3Wem75JRwAjURtEF20fuInDAedTFEsWDd3-trxxwdSVMpE6vuIODjLAwWtyKdr7g-DtcbK7VqlaQa3gv2epKSLZmEOos-f_f2Hl9-x57Q6wQz-Z7tjOvr-AFNotHvZaHfywGFPzcU_6o |
linkProvider | Taylor & Francis |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSNALKs8utGAkroHYnjjOsSCqLXR7aqVyQJbttXtpE7RNqfj3zDjJqiBVPXCLnLEyGs9kHra_Yew9atFyCUYVValkATU--aqmLAW9iYq1F7mmuzjS8xP4elqd3rgLQ8cqKYdOA1BE_leTcVMxejoS95FA0Qzkkoiky1To8mt1nz2oDDp71Ony-3yddEnkZrq5c9vUv3xShu7_B7j09vAzu6H9LfZ4jB_53rDgT9i92D5lDxfjDvkz9mOPB2q4MRxx413i1AjhAvNffpYRpvMwRszuN0cB8HDe9fza_YrEBo4MECUcyUfE1UuO9NdulTCpbp-zk_0vx5_nxdhCoQgYGvWFMUnHKokYMQyBVHrtUiNjcJRWOG9E6bQU0YTgK51KZ6BZehGq0tVQeiXVC7bRdm3cZryG4IIEJxoAiOAdxo5agTZNlHrp_YzBJEQbRnxxanNxbsUIQzrJ3pLs7Sj7GfuwnvZzANi4a8InWqE1MeFj54FudWZHc7PSN8kp4QS6IqiDbKL3ESVhPDpjiGLGmpvra_tcHklDLxOr7mDg3aQMFm2RNlhcG7urSyu1qpWkJt4z9nLQkjWbBDuLSX_z6j--_JY9mh8vDu3hwdG312yTXg2Ykztso19dxV2Mj3r_JhvAHzgiAkE |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSBUXxJvlaSSugfgRxz6Wx2p5tOJAJTggy3bsXkpS7aat-u-ZcZwVIFU9cIscW5mMx5n57Mk3hLwCK-o6qUXV1IJXsoUr37SIUsCbiNh6lvd09w_U6lB--t7M2YSbklaJGDpNRBH5W42L-6RLc0bcG-RE0zLviHD8lwo8fiuukxuNNhyzuuofqy3m4iDM_OPOZUP_ckmZuf8f3tLLo8_shZa3ya0SPtK9ab7vkGuxv0t298sB-T3yc48GrLcxZbjRIVGsg_AL4C89ygTTuRkCZndB4f1pOB5Geu7OIooBLRNDCYXuhXB1Q6H_uVsnwNT9fXK4_PDt3aoqFRSqAJHRWGmdVGwSixGiEJlqr1wyPAaHqMJ5zWqnOIs6BN-oVDstTedZaGrXytoLLh6QnX7o4yNCWxlc4NIxI6WM0jsIHZWQSpvIVef9gshZiTYUenGscnFsWWEhnXVvUfe26H5BXm-HnUz8GlcNeIsztO2M9Ni5YVgf2bLaLPcmOcEcA08k28BN9D6CJrQHXywjWxDz5_zaMe-OpKmUiRVXCPByNgYLSxHPV1wfh9ON5Uq0gmMN7wV5OFnJVkxknQXMbx7_x5NfkN2v75f2y8eDz0_ITbwzMU4-JTvj-jQ-g-ho9M-z_f8GkQEBag |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+correlation+of+thrombin+generation+assay+and+clot+waveform+analysis+in+patients+on+warfarin&rft.jtitle=Hematology+%28Luxembourg%29&rft.au=Cheong%2C+May+Anne&rft.au=Tan%2C+Chuen+Wen&rft.au=Wong%2C+Wan+Hui&rft.au=Kong%2C+Ming+Chai&rft.date=2022-12-31&rft.pub=Taylor+%26+Francis&rft.eissn=1607-8454&rft.volume=27&rft.issue=1&rft.spage=337&rft.epage=342&rft_id=info:doi/10.1080%2F16078454.2022.2043573&rft.externalDBID=0YH&rft.externalDocID=2043573 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1607-8454&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1607-8454&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1607-8454&client=summon |